enGene (NASDAQ:ENGN) Given New $21.00 Price Target at Citizens Jmp

enGene (NASDAQ:ENGN) had its target price hoisted by research analysts at Citizens Jmp from $18.00 to $21.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s target price suggests a potential upside of 126.51% from the company’s previous close.

Other analysts have also recently issued research reports about the stock. Morgan Stanley dropped their target price on shares of enGene from $19.00 to $18.00 and set an “overweight” rating for the company in a research report on Friday, September 12th. Raymond James Financial upgraded enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 target price for the company in a research report on Tuesday. Citigroup reaffirmed a “market outperform” rating on shares of enGene in a research note on Wednesday. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of enGene in a research report on Monday, September 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of enGene in a report on Tuesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.71.

enGene Trading Up 5.1%

ENGN stock traded up $0.45 during midday trading on Wednesday, reaching $9.27. The stock had a trading volume of 365,505 shares, compared to its average volume of 379,681. The firm has a market cap of $474.58 million, a price-to-earnings ratio of -4.94 and a beta of -0.27. enGene has a twelve month low of $2.65 and a twelve month high of $11.14. The company has a quick ratio of 10.34, a current ratio of 10.34 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $7.12 and a two-hundred day simple moving average of $4.92.

enGene (NASDAQ:ENGN) last issued its earnings results on Thursday, September 11th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). As a group, research analysts expect that enGene will post -1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On enGene

Several institutional investors have recently bought and sold shares of the company. Cresset Asset Management LLC bought a new position in shares of enGene during the 2nd quarter worth approximately $36,000. Paloma Partners Management Co bought a new position in shares of enGene in the 2nd quarter valued at about $38,000. PFS Partners LLC bought a new position in shares of enGene in the 3rd quarter valued at about $61,000. ADAR1 Capital Management LLC acquired a new position in enGene during the first quarter valued at approximately $107,000. Finally, Affinity Asset Advisors LLC acquired a new position in shares of enGene during the 2nd quarter worth approximately $280,000. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.